Campylobacter infection in 682 bulgarian patients with acute enterocolitis, inflammatory bowel disease, and other chronic intestinal diseases

2004 ◽  
Vol 49 (1) ◽  
pp. 71-74 ◽  
Author(s):  
Lyudmila Boyanova ◽  
Galina Gergova ◽  
Zoya Spassova ◽  
Radka Koumanova ◽  
Penka Yaneva ◽  
...  
2018 ◽  
Vol 6 (14) ◽  
pp. 745-752 ◽  
Author(s):  
Sha Li ◽  
Long-Gui Ning ◽  
Xin-He Lou ◽  
Guo-Qiang Xu

2021 ◽  
Vol 22 ◽  
Author(s):  
Lorena Ortega Moreno ◽  
Pilar Navarro Sánchez ◽  
Raquel Abalo

: Lipidomics is an emerging and promising branch that analyses the different lipid mole-cules in a biological sample. It is considered a branch of metabolomics, which is defined as the comprehensive analysis of metabolites in a biological specimen. Nonetheless, in recent years lipidomics is becoming a distinct discipline in the biomedicine field. Lipids play important roles in many biological pathways and can work as biomarkers of disease or therapeutic targets for the treatment of diseases. The major lipidomics strategies are shotgun lipidomics and liquid chromatography coupled with mass spectrometry. Gastro-intestinal diseases, such as irritable bowel syndrome or inflammatory bowel disease, are chronic diseases that need non-invasive biomarkers for prognosis and diagnosis. Even more, patients with inflammatory bowel disease are at significantly increased risk of colorectal cancer, principally resulting from the pro-neoplastic effects of chronic intesti-nal inflammation. Current screening methods utilized globally include sigmoidoscopy or standard colonoscopy, but it is important to develop non-invasive and accurate screen-ing tools to facilitate early detection and precise staging of colorectal cancer. Disease progression and response to treatment may also benefit from the application of these potential new tools. This review focuses on studies that use lipidomics approaches to discover potential biomarkers for monitoring the mentioned intestinal diseases and, par-ticularly, tumor progression.


2021 ◽  
Vol 4 (5) ◽  
pp. 75-87
Author(s):  
Cláudio Marcos Rocha-de-Souza ◽  
◽  
Ana Carolina Aor Zaqueu ◽  
Lívia Rodrigues da Cruz ◽  
Marcelo Gomes de Souza ◽  
...  

Canine Inflammatory Bowel Disease (IBD) is the term used to designate a group of chronic intestinal diseases, manifested by persistent or recurrent gastrointestinal signs. Known symptoms are vomiting, diarrhea, changes in appetite and weight loss. Treatment consists of a diet combined with antibiotic therapy and immunosuppressive drugs. It is currently known that changes in the microbiota profile can be used as way to prevent digestive disorders, since some probiotics offer benefits to patients with IBD, reducing symptoms and improving their immunity, however, can say that there is still no consensus regarding the recommendation of the use probiotics in inflammatory bowel diseases.


2018 ◽  
Vol 2 (Supplement_1) ◽  
pp. S73-S80 ◽  
Author(s):  
Charles N Bernstein ◽  
Eric I Benchimol ◽  
Alain Bitton ◽  
Sanjay K Murthy ◽  
Geoffrey C Nguyen ◽  
...  

2019 ◽  
Vol 3 (2) ◽  

Inflammatory bowel disease (IBD) represents a group of intestinal diseases that cause prolonged inflammation of the digestive tract. [The digestive tract comprises the mouth, esophagus, stomach, small intestine and large intestine. It’s responsible for breaking down food, extracting the nutrients and removing any unusable material and waste products. Inflammation anywhere along the digestive tract disrupts this normal process. IBD can be very painful and disruptive and in some cases, it may even be life-threatening.]


2015 ◽  
Vol 13 (3) ◽  
pp. 193 ◽  
Author(s):  
Kang-Moon Lee ◽  
You Sun Kim ◽  
Geom Seog Seo ◽  
Tae Oh Kim ◽  
Suk-Kyun Yang ◽  
...  

2017 ◽  
Vol 15 (3) ◽  
pp. 338 ◽  
Author(s):  
Young Sun Kim ◽  
Sung-Ae Jung ◽  
Kang-Moon Lee ◽  
Soo Jung Park ◽  
Tae Oh Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document